African Americans have a 60% higher incidence of prostate cancer and are about 2 times more likely to die from the disease.
VEGF and PD-1 pathway inhibitors show promising improvements compared with single-agent VEGF pathway inhibitors.
Access a treatment regimen chart with detailed information for renal cell carcinoma, including tyrosine kinase inhibitors and cytokine therapy.
To help curb drug prices, a consortium of hospital groups recently announced plans to form their own nonprofit drug company.
Seven hundred and fifty-one patients were assigned to the 70.2 Gy group and 748 were assigned to the 79.2 Gy group. The median follow-up was 8.4 years.
Erdafitinib — an oral pan-fibroblast growth factor receptor tyrosine kinase inhibitor (FGFR-TKI) — is the first targeted therapy for urothelial cancer.
A previous study showed that using 5-ARIs to treat benign prostate hyperplasia decreased the risk of low-grade PCa.
Larotrectinib may have durable antitumor activity in patients with TRK fusion-positive cancers, regardless of tumor type.
Researchers enrolled 6 and 49 patients into dose-finding and dose expansion stages, respectively.
While patients who received docetaxel had a significant decrease in FACT-P-reported QoL between baseline and 3 months, no difference was noted between baseline and 12 months.
Because tissue biopsy is not always possible in patients with mUC, identifying the optimal targeted therapy or clinical trial can be challenging.
The #MeToo movement has inspired many women to relate stories of harassment, and medicine is no exception.
A study could not determine whether one liquid biopsy panel is more accurate than another overall.
Apalutamide is also the first agent to be approved for meeting the primary endpoint of metastasis-free survival.
The novelty of immunotherapies means that physicians and patients lack extensive experience dealing with them.
New diagnostic and therapeutic tools are in development to inform the management of advanced and metastatic disease.
Patients diagnosed with MIBC are at a significant risk for death — which has not greatly improved in the last few decades.
A shift toward multidisciplinary care is inevitable for the treatment of locally advanced and metastatic RCC.
In separate studies, apalutamide, an investigational agent, and enzalutamide prolonged metastasis-free survival in men with non-metastatic castration-resistant prostate cancer.
COMET-1 and COMET-2 previously showed no overall survival benefit with cabozantinib.
It was previously unknown whether chemotherapy or surveillance leads to improved outcomes in prostate cancer post-prostatectomy.
The impact of this treatment on quality of life was not previously reported.
Previous findings suggested that there were no benefits to overall survival or disease-free survival with VEGF-TKIs vs placebo.
This study was designed to evaluate the efficacy of each treatment using 3-year distant metastasis-free survival as a primary outcome.
Patients with PRCC1 frequently show MET mutations. Crizotinib, a dual inhibitor of MET and ALK, has shown promising activity in MET-altered cancers.
Patients receiving VEGF-TKIs are likely to have treatment dose reductions, delays, or interruptions because of diarrhea, which occurs in about 50% of cases.
Of 542 enrolled patients, 270 were randomly assigned to pembrolizumab and 272 were assigned to chemotherapy. All patients progressed after platinum therapy.
The median follow-up was 17.6 months at time of interim analysis.
Seventy-eight patients with metastatic urothelial carcinoma received intravenous nivolumab until disease progression or discontinuation.
A recent study is the first to demonstrate the cumulative effect of a large number of lifestyle behaviors.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML
- Nicotinamide and Cancer
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma